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Abstract
Background: The presence of lymph nodes (LN) within the prostatic anterior fat pad (PAFP) has been reported in
several recent reports. These PAFP LNs rarely harbor metastatic disease, and the characteristics of patients with
PAFP LN metastasis are not well-described in the literature. Our previous study suggested that metastatic disease to
the PAFP LN was associated with less severe oncologic outcomes than those that involve the pelvic lymph node
(PLN). Therefore, the objective of this study is to assess the oncologic outcome of prostate cancer (PCa) patients
with PAFP LN metastasis in a larger patient population.
Methods: Data were analyzed on 8800 patients from eleven international centers in three countries. Eighty-eight
patients were found to have metastatic disease to the PAFP LNs (PAFP+) and 206 men had isolated metastasis to the
pelvic LNs (PLN+). Clinicopathologic features were compared using ANOVA and Chi square tests. The Kaplan-Meier
method was used to calculate the time to biochemical recurrence (BCR).
Results: Of the eighty-eight patients with PAFP LN metastasis, sixty-three (71.6 %) were up-staged based on the
pathologic analysis of PAFP and eight (9.1 %) had a low-risk disease. Patients with LNs present in the PAFP had a
higher incidence of biopsy Gleason score (GS) 8–10, pathologic N1 disease, and positive surgical margin in
prostatectomy specimens than those with no LNs detected in the PAFP. Men who were PAFP+ with or without PLN
involvement had more aggressive pathologic features than those with PLN disease only. However, there was no
significant difference in BCR-free survival regardless of adjuvant therapy. In 300 patients who underwent PAFP LN
mapping, 65 LNs were detected. It was also found that 44 out of 65 (67.7 %) nodes were located in the middle portion
of the PAFP.
Conclusions: There was no significant difference in the rate of BCR between the PAFP LN+ and PLN+ groups. The PAFP
likely represents a landing zone that is different from the PLNs for PCa metastasis. Therefore, the removal and pathologic
analysis of PAFP should be adopted as a standard procedure in all patients undergoing radical prostatectomy.
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Background
In men undergoing radical prostatectomy (RP), pelvic
lymph node dissection (PLND) is the most accurate and
reliable staging procedure for detecting lymph node
(LN) metastasis in prostate cancer (PCa) [1–4]. Aside
from providing clinicians with the most accurate LN sta-
ging, the therapeutic role of PLND in PCa has emerged
as some have suggested that RP and removal of involved
regional LNs has survival benefit [5–7]. Currently, an ex-
tended template for PLND has been accepted by many
surgeons as the standard due to higher LN yield, in-
creased removal of positive nodes, and fewer missed
positive nodes [8, 9]. Nevertheless, the optimal extent of
PLND that balances potential morbidity with therapeutic
benefit remains controversial.
During RP, Ahlering et al. have proposed that the pros-
tatic anterior fat pad (PAFP) should be dissected to aid
in the identification of the puboprostatic ligaments and
the anterior surface of the dorsal vein complex [10]. In
addition, the potential oncologic rationale for the PAFP
removal has been suggested initially by Kothari et al. in
2001 [11]. Since then, several groups have reported the
presence of LNs in the PAFP and incidence of PAFP LN
metastasis occurring in the range of 5.5 % to 17.0 % and
1.2 % to 2.5 %, respectively [12–16].
Most recently, we have reported the largest series
on the pathologic analysis of LNs and LN metastasis
in the PAFP after reviewing 4,261 patients from 8 in-
stitutions [17]. In this study, PAFP LNs were found in
11.9 % and 0.94 % harbored metastatic disease. More
importantly, our initial study suggested that meta-
static disease to the PAFP LN was associated with
more favorable oncologic outcome than those that in-
volve the PLNs. To further define the oncologic im-
plications of PAFP LN metastasis, we have expanded
the scope of the study to 8800 men from 11 inter-
national institutions.
Methods
Ethics statement
This study was approved by the institutional review board
of all 13 participating institutions (see Additional file 1).
Furthermore, the principles of the Helisinki Declaration
were followed. Each board exempted informed consent
because this was a retrospective study.
Study population
Prospectively maintained database approved by the insti-
tutional review board (IRB) at each institution was ana-
lyzed. Written informed consent was obtained from all
study subjects during the study period between January
of 2006 and February of 2014. In this study, only men
who underwent PAFP excision and pathologic analysis
during open retropubic radical prostatectomy (RRP)
or robot-assisted radical prostatectomy (RARP) were
included. All patients routinely undergo PAFP exci-
sion and pathologic analysis from the thirteen partici-
pating institutions. Initially, the outcomes of 9510
PCa patients were reviewed [RARP, N = 8747 and
RRP, N = 763]. Of these, 8800 PCa patients from
eleven institutions with complete data were selected
for analysis.
The participating thirteen institutions are as follows: Rut-
gers Cancer Institute of New Jersey (New Brunswick, NJ,
USA), University of Pennsylvania (Philadelphia, PA, USA),
Yonsei University (Seoul, Korea), University of California
Irvine (Orange, CA, USA), Asan Medical Center (Seoul,
Korea), Samsung Medical Center (Seoul, Korea), Taichung
Veterans General Hospital (Taichung, Taiwan), Temple
University (Philadelphia, PA, USA), Associated Medical
Professionals (Syracuse, NY, USA), Icahn school of
Medicine at Mount Sinai Hospital (New York, NY,
USA), City of Hope National Medical Center (Duarte,
CA, USA), Kyungpook National University Medical
Center (Daegu, Korea), and Georgetown University
(Washington, D.C., USA).
PAFP removal and pathologic evaluation
PAFP removal and pathological analysis were performed
as described previously [17].
Statistical analysis
For comparison of variables, a student t test or analysis
of variance (ANOVA) test and Pearson χ2 test were used
for analysis of each set of continuous and categorical
data. Biochemical recurrence (BCR) was defined as 2
consecutive PSA increases with the last PSA 0.2 ng/ml
or greater. Multivariate Cox regression analyses were
performed to identify factors predictive of BCR. The
time to BCR was used as the end point for the Kaplan-
Meier model. The log-rank test was used for comparison
with p ≤ 0.05 considered statistically significant. All stat-
istical analyses were performed using the SPSS v.18.0
(IBM Corp., Armonk, NY).
Results
From the eleven international institutions, 8800 patients
underwent pathologic analysis of the PAFP (data not
shown; see Additional file 2) because the number of pa-
tients with LNs present in the PAFP was not available
due to an institutional procedure on not reporting nega-
tive LNs at two sites. Metastatic disease in the PAFP was
detected in eighty-eight patients out of 8800 (0.93 %).
The overall incidence of LNs present in the PAFP was
10.3 % (909/8800).
2835 out of 5260 (53.9 %) patients with available data
on pelvic LNs underwent pelvic LN dissection, with
varying institutional range from 23.2 % to 100.0 %. For
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these patients, the mean (median) number of dissected
total pelvic LN was 6.1 (7) with values in the range of
1–45. Of the ones who underwent pelvic LN dissection,
4.4 % of patients had metastasis to pelvic LN.
Pre- and post-operative patient characteristics of 8800
men with known LN status in the PAFP is known are
summarized in Table 1 with a median follow-up of
18.0 months (range 3.0-84.0 months). In this cohort,
7891 patients were found to have no LNs in the PAFP.
Preoperatively, biopsy Gleason score (GS) was the only
variable significantly different between the two groups.
Specifically, patients with LNs present in the PAFP had
more frequent biopsy GS of 8–10 than those with LNs
absent in the PAFP. Regarding pathologic characteristics
of the RP specimens, statistically significant differences
were found for pathologic LN (N) stage (P = 0.001) and
surgical margin status (P < 0.001).
Table 2 lists the clinicopathologic results of the pa-
tients with metastatic disease to the LNs stratified by
location. Group 1 had isolated metastasis to the pelvic
LNs (PLNs) (n = 206). Group 2 had metastatic disease
limited to the PAFP LNs (n = 63). Group 3 involved dis-
ease both in the pelvic and PAFP LNs (n = 25). Among
the eighty-eight patients with metastasis to the PAFP
LNs, eight (9.1 %) had low-risk disease based on the
D’Amico criteria and sixty-three (71.6 %, Group 2) were
up-staged as a result of the PAFP pathologic analysis.
Compared to men with pelvic LNs metastasis only
(group 1), patients with metastatic disease to the PAFP
LNs (Group 2 and 3) had more aggressive features in bi-
opsy and pathologic GS as well as pathologic stage.
Adjuvant therapy, including androgen deprivation
(ADT), radiation, and chemotherapy was performed more
Table 1 Pre- and post-operative characteristics of patients with
absence or presence of lymph nodes in PAFP
LN absent
in PAFP
LN present
in PAFP
P-value
(N = 7891) (N = 909)
Age, years: mean (SD) 62.7 (7.5) 62.9 (7.7) 0.413
BMI, kg/m2 :mean (SD) 27.9 (3.7) 27.9 (4.2) 0.814
PSA, ng/ml: mean (SD) 8.84 (12.32) 10.00 (24.62) 0.107
Categorical PSA, ng/ml: % 0.814
0-3.9 20.0 22.0
4-9.9 58.3 56.2
10-20 15.1 14.0
>20 6.7 7.8
Biopsy GS: % <0.001
6-7 82.8 78.3
8-10 17.2 21.7
Pathologic GS: % 0.307
6-7 83.8 82.1
8-10 16.7 17.9
Pathologic T stage: % 0.659
T2≥ 67.5 66.8
T3≤ 32.5 33.2
Pathologic N stage: % 0.001
N0/Nx 96.0 93.5
N1 4.0 6.5
Margin status: % <0.001
Negative 82.3 78.1
Positive 17.7 21.9
PAFP, Prostate anterior fat pad; LN, Lymph node; BMI, Body mass index;
PSA, Prostate-specific antigen; GS, Gleason score
Table 2 Differences in clinicopathologic results among the 3
groups stratified by the location of positive lymph nodes.
Group 1,
N = 206
Group 2,
N = 63
Group 3,
N = 25
P-value
Age, years: mean (SD) 63.3 (6.9) 63.3 (7.4) 64.4 (8.1) 0.744
PSA, ng/ml: mean (SD) 21.6 (36.0) 26.9 (85.5) 37.3 (66.5) 0.336
BCR-free survival, months:
mean (range)
19.2
(0.7-77.7)
21.6
(1.0-76.3)
19.6
(2.6-60.0)
0.163
BCR: N (%) 0.073
No 145 (70.4) 35 (55.6) 15 (60.0)
Yes 61 (29.6) 28 (44.4) 10 (40.0)
D’Amico risk: N (%) 0.009
Low risk 29 (14.1) 7 (11.1) 1 (4.0)
Intermediate risk 65 (31.6) 17 (27.0) 1 (4.0)
High risk 112 (54.4) 39 (61.9) 23 (92.0)
Biopsy GS: N (%) <0.001
6-7 116 (56.5) 25 (41.0) 5 (20.0)
8-10 89 (43.4) 36 (59.0) 20 (80.0)
Pathologic GS: N (%) 0.021
6-7 113 (54.9) 29 (46.0) 8 (32.0)
8-10 93 (45.1) 34 (54.0) 17 (68.0)
Pathologic T stage: N (%) 0.005
T2 81 (39.3) 18 (28.6) 3 (12.0)
T3a 48 (23.3) 22 (34.9) 6 (24.0)
T3b 59 (28.6) 19 (30.2) 10 (40.0)
T4 18 (8.7) 4 (6.3) 6 (24.0)
Margin status: N (%) 0.043
Negative 69 (33.5) 37 (58.7) 9 (36.0)
Positive 137 (66.5) 26 (41.3) 16 (64.0)
Adjuvant therapy: N (%) 0.012
No 165 (80.1) 42 (66.7) 16 (64.0)
Yes 41 (19.9) 21 (33.3) 9 (36.0)
Group 1, Pelvic LN metastasis only; Group 2, PAFP LN metastasis only; Group 3,
Both pelvic LN & PAFP LN metastasis; PSA, Prostate-specific antigen;
BCR, Biochemical recurrence; GS, Gleason score
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frequently in men with PAFP LN involvement. 63 out of
71 patients (88.7 %) who were given adjuvant therapy re-
ceived ADT with or without radiation and chemotherapy.
The remaining 8 patients (11.3 %) did not receive ADT
and received radiation, chemotherapy, or both. The me-
dian BCR-free survival period for PLN+, PAFP+, and
PAFP+/PLN+ were 19.2, 21.6, and 19.6 months, respect-
ively. Currently, fifty patients with PAFP LN metastasis re-
main free of BCR.
In order to check whether PAFP LN+ was a surrogate
for extracapsular extension (ECE+), survival analysis of
those with simultaneous ECE+ and PAFP LN+ was com-
pared with that of individuals with ECE- or PAFP LN-.
Although the relative frequency of BCR seemed differ-
ent, the Kaplan-Meier analysis revealed no differences be-
tween the two groups: 46.3 % of ECE+/PAFP LN+ group
had BCR with the median BCR free survival time of
18.0 months. On the other hand, 30.0 % of ECE- or PAFP-
group had BCR with the median BCR free survival time of
15.4 months (P = 0.287). To determine the anatomic lo-
cation of the LNs with in PAFP, LN mapping was car-
ried out at one institution as reported previously [17].
From the cohort of 300 men, the total number of
LNs detected was 65 (Table 3). Of these, 44 (67.7 %)
were located in the middle packet. The numbers of
LNs found in the left and right segments were 11
(16.9 %) and 10 (15.4 %), respectively.
The Multivariate Cox regression model suggested
that higher preoperative PSA was predictive of higher
recurrence rates in all patients (HR 1.005; 95 % CI
1.000-1.009; P = 0.042) and in the subgroup of pa-
tients with adjuvant therapy (HR 1.009; 95 % CI
1.001-1.016; P = 0.019). In addition, PLN+, PAFP LN+,
and PLN+/PAFP LN+ demonstrated comparable risks
of developing BCR (Table 4).
Kaplan-Meier curves were used to assess BCR accord-
ing to the location of the metastatic LNs (Fig. 1). No sta-
tistically significant difference was found in the BCR
when all three groups were compared (Fig. 1a). When
stratified by the administration of adjuvant therapy,
again no difference was observed among the three
groups (Fig. 1b and c).
Discussion
Our international study spanning multiple institutions
has demonstrated that in 8800 patients who underwent
RP, the overall incidence of metastasis in the PAFP LNs
was 0.93 %. Simultaneously, the rate of LNs detected
within the PAFP was 10.3 %. LN mapping within the
PAFP demonstrated that 67.7 % of the LNs were located
in the middle packet. Of the 88 patients with PAFP LN
metastasis, 63 were upstaged as a result of the PAFP
pathologic evaluation.
When clinicopathologic features were analyzed be-
tween men with and without LN in the PAFP, patients
with LNs in the PAFP more frequently had biopsy GS
8–10, N1 disease pathologically, and positive surgical
Table 3 Location of lymph nodes within the PAFP
Total # Patients 300
Number of Nodes Detected 657
Middle (# of Nodes) 44
Left (# of Nodes) 11
Right (# of Nodes) 10
Table 4 Multivariate Cox regression analyses to identify
predictors of biochemical recurrence
Variables HR 95 % CI P-value
Lower Upper
All patients
Age 1.008 .979 1.038 .604
Preoperative PSA 1.005 1.000 1.009 .042
Post-operative GS (≤7 vs. ≥8) 1.264 .822 1.943 .286
Pathologic stage (T2 vs. T3) .931 .584 1.484 .763
Margin status (Negative vs. Positive) 1.159 .745 1.803 .514
Pelvic and PAFP LN metastasis status
Group 1 1 - - -
Group 2 1.335 .821 2.169 .244
Group 3 1.288 .639 2.594 .479
Patients without adjuvant therapy
Age 1.020 .985 1.055 .265
Preoperative PSA 1.003 .996 1.009 .423
Post-operative GS (≤7 vs. ≥8) 1.094 .648 1.848 .737
Pathologic stage (T2 vs. T3) 1.024 .601 1.746 .930
Margin status (Negative vs. Positive) 1.094 .648 1.848 .555
Pelvic and PAFP LN metastasis status
Group 1 1 - - -
Group 2 1.350 .754 2.418 .312
Group 3 1.064 .406 2.792 .899
Patients with adjuvant therapy
Age .994 .933 1.059 .842
Preoperative PSA 1.009 1.001 1.016 .019
Post-operative GS (≤7 vs. ≥8) 1.925 .774 4.788 .159
Pathologic stage (T2 vs. T3) .727 .250 2.117 .559
Margin status (Negative vs. Positive) 1.316 .467 3.711 .604
Pelvic and PAFP LN metastasis status
Group 1 1 - - -
Group 2 1.633 .600 4.446 .337
Group 3 2.592 .857 7.842 .092
HR, hazard ratio; CI, confidence interval; Group 1, Pelvic LN metastasis only; Group 2,
PAFP LN metastasis only; Group 3, Both pelvic LN & PAFP LN metastasis
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margins. In comparison to the patients with isolated me-
tastasis to the pelvic LNs, men with PAFP LNs metasta-
sis had worse pathologic features. Yet, there was no
significant difference in BCR free survival when the data
were assessed based on the location of the metastasis
(pelvic LN+, PAFP LN+, or pelvic LN+/PAFP LN+).
Collectively, these observations suggest that the PAFP
should be removed in all patients undergoing RP and
that the oncologic implication of PAFP LN metastasis is
equivalent to that of pelvic LN involvement in men with
PCa.
Previously, our group reported on the detailed ana-
lysis of 40 patients with metastatic PCa to the PAFP
LNs [17]. Because this original report was largely fo-
cused on the clinicopathologic features of men with
PAFP LN metastasis, we designed the current study
to assess the oncologic implications of PAFP LN in-
volvement in men with PCa. To this end, we have in-
creased the sample size to 9510 by increasing the
number of participating institutions to thirteen. The
study sites represent fourteen urologic surgeons from
three different countries – USA, South Korea, and
Taiwan.
A careful analysis of 8800 men after excluding patients
with incomplete data revealed that men with LNs
present in the PAFP were more likely to have aggressive
disease as indicated by the higher frequency of biopsy
GS 8–10 PCa, pathologic stage N1, and positive surgical
margin. In a significantly smaller sample size of 356 men,
Hansen et al. similarly reported that pathologic N1 disease
was more frequently detected in patients who harbor LNs
within the PAFP than those without LNs within the PAFP
(21.1 % vs. 7 %, P = 0.02) [14]. In addition, it has been sug-
gested that patients with LNs found in the PAFP were
younger (60.5 vs. 65.0, P = 0.002) [13] while Jeong et al.
noted that the mean preoperative PSA level was
significantly higher in patients with LNs present in the
PAFP (7.70 vs. 6.01, P = 0.039) [15]. But in the present
study, age and PSA did not show any differences be-
tween the two groups.
Clinically, the current study demonstrated that the
outcome of men with metastatic PCa to the PAFP LNs
is similar to that of patients with pelvic LN metastasis.
To assess the oncologic significance of PAFP LN metas-
tasis in men with PCa, we have compared the outcome
based on the location of the positive LNs (pelvic LN
only, PAFP LN only, and pelvic LN+/PAFP LN+) in
both Cox regression model as well as Kaplan-Meier
survival analysis. Pathologic analysis revealed that men
with PAFP LN involvement, regardless of the pelvic LN
status, had more aggressive features. Nevertheless, BCR
free survival duration was not significantly different
among the three groups. More importantly, this lack of
difference in BCR free survival period was present re-
gardless of adjuvant therapy (P = 0.469). Moreover,
among 88 patients with PAFP LN+, there were 67 pa-
tients who had simultaneous ECE+ and PAFP LN+, il-
lustrating a high level of correlation. The risk of BCR in
the above group was highly elevated although no statis-
tical difference was found when compared to those with
ECE- or PAFP-: (31/67) 46.3 % vs. (68/227) 30.0 %, re-
spectively (P = 0.287). Taken together, these findings
suggest that PCa patients with metastasis to the PAFP
LNs should be treated as those with pelvic LN
metastasis.
Finally, results of the present study provide multiple
reasons for the PAFP removal and pathologic analysis in
all men undergoing RP. First, the PAFP LNs are likely an
independent and separate anatomic landing zone for PCa
metastasis. In our group’s initial publication, we have re-
ported that the LNs within the PAFP overwhelmingly
mapped to the middle packet [17]. In this update, we have
Fig. 1 Kaplan-Meier curves for BCR-free survival according to the location of metastatic lymph nodes in (a) all patients (b) patients without
adjuvant therapy, and (c) patients with adjuvant therapy
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increased the sample size and carried out LN mapping in
300 patients. Again, a significant majority (67.7 %) of the
LNs in PAFP were located in the middle packet. Accord-
ingly, the detection of LNs within PAFP is not likely a re-
sult of an incomplete dissection of the obturator LNs.
Second, the pathologic analysis of PAFP enhances the ac-
curacy of staging. Of the 88 men with metastatic disease
to the PAFP LNs, 63 were upstaged based on the PAFP
LNs involvement. Third, there are no reliable pre-
operative parameters that predict the PAFP LN metastasis.
Although no preoperative imaging is currently recom-
mended for the detection of PAFP LN metastasis and for
guidance in removing PAFP LN, the added surgical step in
the absence of imaging modality will not likely comprom-
ise the quality of surgical outcomes. In our aforemen-
tioned initial multi-institution study that analyzed forty
patients with PAFP LN disease, only three had a low-risk
disease defined by the D’Amico criteria pre-operatively.
Based on this observation, we suggested that the patho-
logic analysis of PAFP may not be necessary in men with
low-risk PCa. However in the current study, 9.1 % had
low-risk disease. Accordingly, all PAFP specimens should
be analyzed pathologically. Fourth, there may be a thera-
peutic effect of PAFP removal. Of the 88 men with PAFP
LN metastasis, fifty remain free of BCR. Taken together
with the minimal surgical morbidity of PAFP dissection,
we now contend that the removal and pathologic examin-
ation be a standard procedure in all patients undergoing
RP.
Notwithstanding the strength of the largest sample size
to date on this topic, our study is not without weaknesses.
First, the number of men with PAFP LN metastasis was
only 88. Given this small number of event, it is entirely
possible that there is a unique oncologic implication of
PAFP LN metastasis that requires a larger sample size to
uncover. Indeed in this cohort, PAFP LN involvement,
regardless of the pelvic LN status, had more aggressive
pathologic features. Second, additional follow-up is ne-
cessary to evaluate cancer-specific and overall survival.
Third, BCR comparisons among pelvic LN+, PAFP LN+,
and PAFP LN+/Pelvic LN+ groups were likely confounded
because a greater proportion of men with PAFP LN+ with
and without pelvic LN+ (group 2 and 3) received adjuvant
therapy than the men with pelvic LN+ only (group 1)
(P = 0.012) (Table 2). Because adjuvant therapy may lower
BCR, adjuvant therapy-adjusted BCR in group 2 and 3,
may in fact, be higher. Hence, this finding may further
support the substantial BCR risk associated with PAFP
metastasis. We plan to continue increasing the overall
sample size and track the patients with PAFP LN metasta-
sis to determine the long-term oncologic outcome. In the
meantime, the present study provides the relative confi-
dence that PCa patients with PAFP LN metastasis should
be treated as those with pelvic LN disease.
Conclusions
Metastasis to the PAFP LNs and pelvic LNs had equiva-
lent duration of BCR free survival. Because the PAFP is
likely an anatomically independent and separate landing
zone of PCa metastasis, the PAFP should be removed
and analyzed in all men undergoing RP.
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